Shepard Colin W, Soriano-Gabarro Montse, Zell Elizabeth R, Hayslett James, Lukacs Susan, Goldstein Susan, Factor Stephanie, Jones Joshua, Ridzon Renee, Williams Ian, Rosenstein Nancy
Centers for Desease Control and Prevention , Atlanta, Georgia 30333, USA.
Emerg Infect Dis. 2002 Oct;8(10):1124-32. doi: 10.3201/eid0810.020349.
We collected data during postexposure antimicrobial prophylaxis campaigns and from a prophylaxis program evaluation 60 days after start of antimicrobial prophylaxis involving persons from six U.S. sites where Bacillus anthracis exposures occurred. Adverse events associated with antimicrobial prophylaxis to prevent anthrax were commonly reported, but hospitalizations and serious adverse events as defined by Food and Drug Administration criteria were rare. Overall adherence during 60 days of antimicrobial prophylaxis was poor (44%), ranging from 21% of persons exposed in the Morgan postal facility in New York City to 64% of persons exposed at the Brentwood postal facility in Washington, D.C. Adherence was highest among participants in an investigational new drug protocol to receive additional antibiotics with or without anthrax vaccine--a likely surrogate for anthrax risk perception. Adherence of <60 days was not consistently associated with adverse events.
我们在暴露后抗菌预防活动期间以及在抗菌预防开始60天后对一项预防计划进行评估时收集了数据,该预防计划涉及美国六个发生炭疽杆菌暴露地点的人员。预防炭疽的抗菌药物预防相关不良事件常见,但按照美国食品药品监督管理局标准定义的住院和严重不良事件很少见。抗菌预防60天期间的总体依从性较差(44%),范围从纽约市摩根邮政设施暴露人员的21%到华盛顿特区布伦特伍德邮政设施暴露人员的64%。在接受含或不含炭疽疫苗的额外抗生素的研究性新药方案参与者中,依从性最高——这可能是炭疽风险认知的一个替代指标。少于60天的依从性与不良事件之间并无一致关联。